When Novartis dissolved its gene and cell therapy unit a few years ago, a bunch of projects the Swiss pharma giant had incubated were tossed aside. One of them was the work of surgeon Suzanne Ildstad, who has spent decades trying to develop a new way to improve the health outcomes of patients who need organ transplants.

That work has just been salvaged. If it plays out as Ildstad hopes, her company might not only help transform treatment for kidney failure patients—but possibly, for people suffering from other illnesses, such as autoimmune disorders.

Talaris Therapeutics, a Louisville, KY, startup founded by… Read more »

UNDERWRITERS AND PARTNERS